中国生物制药（01177.HK）今日盘中大涨5.12%，引发市场关注。该公司股价走强主要受以下因素推动：
首先，中国生物制药于7月15日晚间宣布，拟以不超过9.51亿美元（约合人民币68.22亿元）收购礼新医药95.09%股权。加上此前持有的4.91%股权，交易完成后礼新医药将成为中国生物制药全资子公司。此次收购将显著扩充中国生物制药的创新药管线，尤其是在肿瘤领域的研发实力，有望增强公司的核心竞争力和国际影响力。
其次，公司执行董事谢炘于7月16日增持100万股公司股份，每股作价6.47港元，涉资约647万港元。高管增持往往被视为对公司未来发展的信心，可能进一步提振了投资者信心。这些积极因素共同推动了中国生物制药股价的强劲表现，反映出市场对公司战略布局和发展前景的看好。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.